70
Participants
Start Date
March 31, 2003
Primary Completion Date
August 31, 2007
Study Completion Date
August 31, 2007
Pegylated Lyposomal Doxorubicin
Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Cyclophosphamide
Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Princess Margaret Hospital, Canada
OTHER
Merck Sharp & Dohme LLC
INDUSTRY